Call for Abstract

3rd International Conference & Exhibition on Tissue Preservation and Biobanking, will be organized around the theme “New Scientific Innovations in Development of Tissue science and Biobanking Technologies”

Biobanking 2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Biobanking 2017

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Tissue engineering is emerging as a significant potential alternative or complementary solution, whereby tissue and organ failure is addressed by implanting natural, synthetic, or semisynthetic tissue and organ mimics that are fully functional from the start, or that grow into the required functionality. Initial efforts have focused on skin equivalents for treating burns, but an increasing number of tissue types are now being engineered, as well as biomaterials and scaffolds used as delivery systems. A variety of approaches are used to coax differentiated or undifferentiated cells, such as stem cells, into the desired cell type. Notable results include tissue-engineered bone, blood vessels, liver, muscle, and even nerve conduits. As a result of the medical and market potential, there is significant academic and corporate interest in this technology.

  • Track 1-1Development of New Biomaterial Scaffolds for Tissue Engineering
  • Track 1-2 Tissue Engineering and Biomaterial Concepts
  • Track 1-3 Challenges to Commercialization of Tissue Engineering Products
  • Track 1-4Ethics issues in tissue engineering
Biomaterials are being used for the healthcare applications from ancient times. But subsequent evolution has made them more versatile and has increased their utility. Biomaterials have revolutionized the areas like bioengineering and tissue engineering for the development of novel strategies to combat life threatening diseases. Together with biomaterials, stem cell technology is also being used to improve the existing healthcare facilities. These concepts and technologies are being used for the treatment of different diseases like cardiac failure, fractures, deep skin injuries, etc. Introduction of nanomaterials on the other hand is becoming a big hope for a better and an affordable healthcare. 
  • Track 2-1Biomaterials in Biological Engineering
  • Track 2-2Big Data Analytics & Bioinformatics for Biomarkers Development
  • Track 2-3Combinatorial approaches to biomaterial design
  • Track 2-4Overcoming Commercialization Challenges in Biomarker Development

A Biorepository is a biological materials repository that collects, processes, stores, and distributes bio specimens to support future scientific investigation. Biorepositories can contain or manage specimens from animals, including humans, and many other living organisms. Vertebrates, invertebrates, arthropods, and other life-forms are just a few of the many classes of living organisms which can be studied by preserving and storing samples taken. The Biorepository assures the quality, and manages the accessibility and distribution/disposition of the bio specimens in its collection. There are a huge number of biorepositories in the United States, which shift broadly by size, the sort of biospecimen gathered, and reason. One of the biorepository's most elevated needs is ensuring the security and sacredness of individual and medicinal data. bio specimens are materials taken from the human body, for example, tissue, blood, plasma, and pee that can be utilized for growth determination and investigation. At the point when patients have a biopsy, surgery, or other methodology, regularly a little measure of the example evacuated can be put away and utilized for later research. Once these specimens have been legitimately prepared and put away they are known as human bio specimens. Specialists and scientists might break down biospecimen to search for signs of ailment in the contributor. Bio specimens can affirm whether a malady is available or truant in a specific patient; however they likewise give other data that might be valuable to the doctor or a specialist. Every example might contain DNA, proteins, and different particles essential for comprehension ailment movement.

ESBB gathering Johannesburg, South Africa, Global Biobanking London, UK, World Conference on Regenerative Medicine 2015 Leipzig, Germany, Hands On Biobanks 2016 meeting Vienna, Austria, Genomic Sample Prep and Biomarker Assay Development San Francisco, USA, Phacilitate Cell and Gene Therapy World Washington D.C., USA, Keystone Stem Cells and Regeneration in the Digestive Organs (X6) Keystone, Colorado, USA, Keystone Cardiac Development, Regeneration and Repair (Z2) Snowbird, Utah, USA, Tissue Niches and Resident Stem Cells in Adult Epithelia Gordon Research Conference Hong Kong, China, EMBL Hematopoietic Stem Cells: From the Embryo to the Aging Organism Heidelberg, Germany

  • Track 3-1Biospecimen Security And Storage
  • Track 3-2Impacts on collection of samples and research
  • Track 3-3Biospecimen lifecycle and process chain quality requirements
  • Track 3-4Tissue Banking, Specimen Evaluation, and Scientific Advancement
  • Track 3-5Challenges and latest strategies for successful samples collection
  • Track 3-6Bio-repository & Sample management
  • Track 3-7Biospecimens & Frozen tissue

A process where cells, whole tissues, or any other substances susceptible to damage caused by chemical reactivity or time are preserved by cooling to sub-zero temperatures. At low enough temperatures, any enzymatic or chemical activity which might cause damage to the material in question is effectively stopped. Cryopreservation methods seek to reach low temperatures without causing additional damage caused by the formation of ice during freezing. Traditional cryopreservation has relied on coating the material to be frozen with a class of molecules termed cryoprotectants. New methods are constantly being investigated due to the inherent toxicity of many cryoprotectants. By default it should be considered that Cryopreservation alters/compromises the structure and function of cells unless it is proven otherwise for a particular cell population. Tissue and fluid preservation, also known as biobanking, biorepository science, or cryopreservation often referred to as cryobanking has become mainstream and big business. According to research by the British Broadcasting Corporation, the global biobanking market in 2010 was over $140 billion dollars, with a projected 30% increase by the year 2015 towards fostering biobanking initiatives.

World Conference on Regenerative Medicine 2015 Leipzig, Germany, Biomarkers for Cancer Immunotherapy San Francisco, USA, Biomarkers & Diagnostics World Congress Philadelphia, USA, ESBB conference Johannesburg, South Africa, ART World Congress Symposium on Safe and Efficient IVF New York City, USA, Tissue Niches & Resident Stem Cells in Adult Epithelia Gordon Research Conference Hong Kong, China, EMBL Hematopoietic Stem Cells: From the Embryo to the Aging Organism Heidelberg, Germany, Keystone Cardiac Development, Regeneration and Repair (Z2) Snowbird, Utah, USA, Stem Cells: from Basic Biology to Therapeutic Application Suzhou, China, Keystone Stem Cells and Regeneration in the Digestive Organs (X6) Keystone, Colorado, USA.

Increase in funding for these studies and research of stem cells would also trigger the growth of this market. In 2013, the government of Japan funded around USD 1.12 billion for stem cell studies. Moreover, advancement in technologies may also boost the growth of this market. Medical experts are becoming increasingly inclined towards the use of bioengineered products, which are more compatible with the human body. Increase in drug manufacturing through stem cells will also enhance the growth of this market. Recently, stem cells proved to be helpful in treating spinal muscular atrophy. It has been reported that in 2013, around 30,000 kids in the U.S. suffer from spinal muscular atrophy. Stem cell-based drugs would help in curing such complex diseases, which would again support the growth of this market.

  • Track 4-1Cryopreservation Of Human Ovarian Tissue
  • Track 4-2Cryopreservation Equipment In Stem Cells
  • Track 4-3Cryobiology, Cryoinjury and Cryoprotection
  • Track 4-4Cropreservative Reagents Market Forecasts
  • Track 4-5Medical and social aspects of cryopreservation of oocytes for fertility preservation

Although most living organisms are composed of large amounts of water, it is not inevitable that freezing these organisms results in ice-formation. Among amphibians and insects that can tolerate freezing, there is wide variation in the amount of freezing they can tolerate. Species of frogs can spend days or weeks "with as much as 65 percent of their total body water as ice". Some amphibians achieve their protection due to the glycerol manufactured by their livers. Glycerol is "antifreeze", it reduces ice formation and lowers freezing point. Glycerol (glycerin), like ethylene glycol (automobile anti-freeze) is cryoprotectants. The sugar glucose is also cryoprotectants — and arctic frogs have a special form of insulin that accelerates glucose release and absorption into cells as temperatures approach freezing. Cryoprotectants can make water harden like glass — with no crystal formation — a process called Vitrification. Freezing-damage to cells is due to the formation of ice-crystals. Entire organs can be solidified and stored at temperatures as low as -140° C. Scientists are working on ways to reduce the toxicity of the cryoprotectants used to make water vitrify to allow banking of organs for transplantation. At Alcor, we are optimistic that the toxicity that still does occur with vitrification of human organs will be reversible with future molecular repair technology.

World Conference on Regenerative Medicine 2015 Leipzig, Germany, HandsOn Biobanks 2016 conference Vienna, Austria, ESBB conference Johannesburg, South Africa, Global Biobanking London, UK, Genomic Sample Prep and Biomarker Assay Development San Francisco, USA, Keystone Stem Cells and Cancer Breckenbridge, CO, USA, ISSCR Pluripotency: From basic science to therapeutic applications Kyoto, Japan, Tissue Niches & Resident Stem Cells in Adult Epithelia Gordon Research Conference Hong Kong, China, Craniofacial Morphogenesis & Tissue Regeneration Ventura, CA, USA, Phacilitate Cell & Gene Therapy World Washington D.C., USA.

Increase in funding for these studies and research of stem cells would also trigger the growth of this market. In 2013, the government of Japan funded around USD 1.12 billion for stem cell studies. Moreover, advancement in technologies may also boost the growth of this market. Medical experts are becoming increasingly inclined towards the use of bioengineered products, which are more compatible with the human body. Increase in drug manufacturing through stem cells will also enhance the growth of this market. Recently, stem cells proved to be helpful in treating spinal muscular atrophy. It has been reported that in 2013, around 30,000 kids in the U.S. suffer from spinal muscular atrophy. Stem cell-based drugs would help in curing such complex diseases, which would again support the growth of this market.

  • Track 5-1Vitrification versus slow freezing
  • Track 5-2Short term and Long term tissue preservation
  • Track 5-3Human blastocyst vitrification and warming
  • Track 5-4Biosafety of vitrification - the issue of contamination using an open system
  • Track 5-5Effect of different vitrification solutions and procedures

Biomedical investigators require high quality human tissue to support their research; thus, an important aspect of the provision of tissues by biorepositories is the assurance of high quality and consistency of processing specimens. This is best accomplished by a quality management system (QMS). The basis of a QMS program designed to aid biorepositories that want to improve their operations. In 1983, the UAB Tissue Collection and Biobanking Facility (TCBF) introduced a QMS program focused on providing solid tissues to support a wide range of research; this QMS included a quality control examination of the specific specimens provided for research. Similarly, the Division of Laboratory Sciences at the Centers for Disease Control and Prevention (CDC) introduced a QMS program for their laboratory analyses, focused primarily on bodily fluids. The authors of this article bring together the experience of the QMS programs at these two sites to facilitate the development or improvement of quality management systems of a wide range of biorepositories.

 

 

  • Track 6-1Role of QMS in improving of biobank standards
  • Track 6-2Forensic Study of Identity
  • Track 6-3Sample integrity and quality assured biobanking
  • Track 6-4Accreditation and Certification of Biobanks
  • Track 6-5QMS implementation in maintenance and sustainability of biobanks

Ethical issues are commonly present in many aspects of Biobanking. The fact that Biobanks deal with human samples, invading an individual autonomy or limiting self-control, provokes a number of ethical issues. Who is actually competent to give informed consent and donate a sample? When individuals donate part of their body to a biobank, how is that human sample processed? Who is the owner of the sample? Who should decide how it should be used? Who has the right to know individual results of research? These and many more ethical dilemmas exist in the ethical framework of biobanks. With the recent rapid developments in biobanking, all of these issues are magnified with plenty of further new questions continuously arising. Ethical framework has been the most controversial issue in the domain of biobanking. Thus, it is not surprising that there is a substantial literature focusing on ethical dilemmas in biobanking, such as informed consent, privacy, protection, and returning of results to participants. For many years, researchers at CRB have provided constructive advice on how to deal with ethical aspects of research using human tissue material and personal data. For more than 80 years tissue has been derived from human bodies, stored, distributed and used for therapeutic, educational, forensic and research purposes as part of healthcare routine in most western countries.

American Society for Bioethics and Humanities Houston, USA, Association of Bioethics World Congress Edinburgh, UK, Oxford Global Health and Bioethics International Conference Oxford shire, UK, CFP: Global Forum on Bioethics in Research Foundation Merieux, France, Hands On Biobanks 2016 conference Vienna, Austria, Global Biobanking London, UK, The Biomarker Conference Orlando, Florida – USA, ART World Congress Symposium on Safe and Efficient IVF New York City, United States, VIII International Postharvest Symposium: Enhancing Supply Chain and Consumer Benefits - Ethical and Technological Issues Cartagena, Murcia, Spain.

According to estimates from the World Bank, global healthcare spending increased at a CAGR of 6.97% from 2003 to 2013, from USD 3,786 Billion in 2003 to USD 7,427 Billion in 2013. In this period, public healthcare spending increased at a CAGR of 7.28%, from USD 2,198 Billion in 2003 to USD 4,440 Billion in 2013. This high growth rate, along with the substantial size of healthcare spending, will act as an important driver for biobanks, hospitals and gene banks, which are the major end-user segments of the biopreservation media & equipment market.

  • Track 7-1Ownership, Property Rights and Commercialization in Relation to Biobanking
  • Track 7-2Ethical considerations surrounding biobanking and biorepository operation.
  • Track 7-3Legal and Ethical Framework For Collaborative Biobanking Across Europe
  • Track 7-4Factors Influencing Biobanks Prices
  • Track 7-5Ethical issues & future use of samples
  • Track 8-1Sample and data sharing in biobanks
  • Track 8-2Public trust in health information sharing
  • Track 8-3Ownership and access to personal genetic information in biobanks

Biorepositories provide a resource for researchers to increase understanding of complex diseases. Studies such as the Lung Genomics Research Consortium (LGRC), a two-year project launched in October 2009, are going a step further than standard biobanking practices and characterizing the samples with their molecular makeup. The molecular data can then be mined along with the clinical data. Led by National Jewish Health and funded by the National Heart, Lung and Blood Institute, a division of the National Institutes of Health (NIH), the LGRC project consists of five institutions, including Dana-Farber Cancer Institute. Collaborators in the project work with samples banked at the Lung Tissue Research Consortium (LTRC), which houses tissue samples and blood from lung disease sufferers, primarily chronic obstructive pulmonary disease (COPD), along with a rich set of clinical data from patients

Immuno-Oncology London UK, Next-Generation Cancer Immunotherapies San Diego, USA, ESBB conference Johannesburg, South Africa, HandsOn Biobanks 2016 conference Vienna, Austria, American Society for Bioethics and Humanities Houston, USA, Craniofacial Morphogenesis & Tissue Regeneration Ventura, CA, USA, ISSCR Pluripotency: From basic science to therapeutic applications Kyoto, Japan, Craniofacial Morphogenesis & Tissue Regeneration Ventura, CA, USA, Phacilitate Cell & Gene Therapy World Washington D.C., USA, Notch Signaling in Development, Regeneration & Disease Gordon Research Conference Lewiston, ME, USA.

The biobanking market is poised for explosive growth if it can overcome the challenges of an adolescent industry. According to an August 2012 Infiniti Research report titled “Global Biobanking Market 2011-2015,” the biobanking market will increase 30 per cent from 2011 to 2015 to nearly $183 billion. Growth is being driven by an increase in population genetics studies, personalized medicine, and the use of genetic information in food safety, forensics, and disease surveillance.

  • Track 9-1Identification of useful biomarkers
  • Track 9-2New challenges confronting the preservation sciences
  • Track 9-3Challenges and latest strategies for successful samples collection.
  • Track 9-4Pathology databanking and biobanking

The sequencing of the human genome, completed at the dawn of the twenty-first century, allows researchers to integrate new data on genetic risk factors with demographic and lifestyle data collected via modern communication technologies. The technical prerequisites now exist for merging these cascades of molecular genetic information, not only to national health registers, but also to epidemiology and clinical data. Long-term storage of biological materials and data is a critical component of any epidemiological or clinical study. In designing Biobanks, informatics plays a vital role for the handling of samples and data in a timely fashion. Biobank Informatics contains important elements concerning definition, structure, and standardization of information that has been gathered from a multitude of sources from population-based registries, biobanks, patient records, and from large-scale molecular measurements.

Bioinformatics for Big Data San Francisco, USA, Immuno-Oncology London UK, Next-Generation Cancer Immunotherapies San Diego, USA, ESBB conference Johannesburg, South Africa, Global Biobanking London, UK, Keystone Stem Cells and Regeneration in the Digestive Organs (X6) Keystone, Colorado, USA, ISSCR Pluripotency: From basic science to therapeutic applications Kyoto, Japan, Keystone Cardiac Development, Regeneration and Repair (Z2) Snowbird, Utah, USA, The Stem Cell Niche–Development & Disease Hillerød, Denmark, EMBL Hematopoietic Stem Cells: From the Embryo to the Aging Organism Heidelberg, Germany

  • Track 10-1Software solutions development for biobanking
  • Track 10-2Technology transfer in biobanking
  • Track 10-3Integrating biobanks
  • Track 10-4Sample storage management system for biobanks
  • Track 10-5Bioinformatics Infrastructure of a Nutrigenomics Biobank

Fertility preservation is the effort to help cancer patients retain their fertility, or ability to procreate. Research into how cancer affects reproductive health and preservation options are growing, sparked in part by the increase in the survival rate of cancer patients. The main methods of fertility preservation are ovarian protection by GnRH agonists, cryopreservation of ovarian tissue, eggs or sperm, or of embryos after in vitro fertilization. The patient may also choose to use egg or sperm from a donor by third party reproduction rather than having biological children.

ART World Congress Symposium on Safe and Efficient IVF New York City, USA, Global Biobanking London, UK, The Biomarker Conference Orlando, Florida, USA, World Conference on Regenerative Medicine 2015 Leipzig, Germany, ESBB conference Johannesburg, South Africa, World Conference on Regenerative Medicine 2015 Leipzig Germany, Keystone Stem Cells and Regeneration in the Digestive Organs (X6) Keystone, Colorado, USA, Molecular and Cellular Basis of Growth and Regeneration (A3) Breckenridge, Colorado, USA, Keystone Cardiac Development, Regeneration and Repair (Z2) Snowbird, Utah, USA, Tissue Niches & Resident Stem Cells in Adult Epithelia Gordon Research Conference Hong Kong, China.

According to estimates from the World Bank, global healthcare spending increased at a CAGR of 6.97% from 2003 to 2013, from USD 3,786 Billion in 2003 to USD 7,427 Billion in 2013. In this period, public healthcare spending increased at a CAGR of 7.28%, from USD 2,198 Billion in 2003 to USD 4,440 Billion in 2013. This high growth rate, along with the substantial size of healthcare spending, will act as an important driver for biobanks, hospitals and gene banks, which are the major end-user segments of the biopreservation media & equipment market.

  • Track 11-1New advances in male fertility preservation
  • Track 11-2Embryo, Sperm, Oocyte Storage
  • Track 11-3Fertility, tissue and organ preservation
  • Track 11-4In vitro Fertilization (IVF) Therapy
  • Track 11-5Fertility Biobank for Future Research

Stem cells contribute to innate healing and harbor a promising role for regenerative medicine. Stem cell banking through long-term storage of different stem cell platforms represents a fundamental source to preserve original features of stem cells for patient-specific clinical applications. Stem cell research and clinical translation constitute fundamental and indivisible modules catalyzed through biobanking activity, generating a return of investment.

  • Track 12-1Biobanks for Pluripotent Stem Cells
  • Track 12-2Protection of human stem cells
  • Track 12-3Fetal stem cell Banking
  • Track 12-4Challenging the gaps in global cancer stem cell Biobanks
  • Track 12-5Ethical Issues in Stem Cell banking

The Germplasm Bank is committed to providing healthy and viable seed, as well as reliable information on the collections of maize and wheat genetic resources it preserves; carrying out the activities required for seed introduction, processing, conservation, and distribution; complying with international agreements and standards; and hiring qualified staff to ensure that the requirements of our clients are met. The Bank is thus committed to complying with ISO 9001:2008 and continually improving the effectiveness of the Quality Management System. The Global Plan of Action (GPA) for plant genetic resources for food and agriculture aims to promote the conservation, sustainable utilization, and fair and equitable sharing of benefits of plant genetic resources. It is designed to contribute to the implementation of the Convention on Biological Diversity in the field of food and agriculture. The Plant Genetic Resource Center's specially designed vaults currently hold some 28,000 samples of maize and teosinte, a wild relative of maize, and 140,000 Triticeae samples, including bread wheat, durum wheat, and triticale (a man-made crop developed by crossing wheat with rye), with significant collections of barley, rye, and primitive and wild relatives of wheat. The Center also maintains a living collection of Tripsacum, a more distant maize relative.

ESBB conference Johannesburg, South Africa, Global Biobanking London, UK, HandsOn Biobanks 2016 conference Vienna, Austria, Managing Biomarker-Driven Clinical Trials Miami, USA, Genomic Sample Prep and Biomarker Assay Development San Francisco, USA, 2nd International Symposium on Germplasm of Ornamentals Atlanta, Georgia, IX International Symposium on In Vitro Culture and Horticultural Breeding Giza, Egypt, International Symposium on Role of Plant Genetic Resources on Reclaiming Lands and Environment Deteriorated by Human and Natural Actions Shiraz, Iran, VIII International Postharvest Symposium: Enhancing Supply Chain and Consumer Benefits - Ethical and Technological Issues Cartagena, Murcia, Spain.

According to estimates from the World Bank, global healthcare spending increased at a CAGR of 6.97% from 2003 to 2013, from USD 3,786 Billion in 2003 to USD 7,427 Billion in 2013. In this period, public healthcare spending increased at a CAGR of 7.28%, from USD 2,198 Billion in 2003 to USD 4,440 Billion in 2013. This high growth rate, along with the substantial size of healthcare spending, will act as an important driver for biobanks, hospitals and gene banks, which are the major end-user segments of the biopreservation media & equipment market.

  • Track 13-1Seed bank
  • Track 13-2Spores and Mushroom Spores Bank
  • Track 13-3Artificial seed production
  • Track 13-4Plant Biobank